Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT04435366
Registration number
NCT04435366
Ethics application status
Date submitted
12/05/2020
Date registered
17/06/2020
Date last updated
12/12/2024
Titles & IDs
Public title
A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)
Query!
Scientific title
A Phase 3 Multicenter, Randomized, Double Masked, Sham- Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Query!
Secondary ID [1]
0
0
ISEE2008
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Geographic Atrophy
0
0
Query!
Macular Degeneration
0
0
Query!
Condition category
Condition code
Eye
0
0
0
0
Query!
Diseases / disorders of the eye
Query!
Other
0
0
0
0
Query!
Research that is not of generic health relevance and not applicable to specific health categories listed above
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Avacincaptad Pegol
Treatment: Drugs - Sham
Experimental: Avacincaptad Pegol - Participants received avacincaptad pegol (ACP) 2 milligram (mg)/eye via intravitreal (IVT) injections monthly through Month 11 (Year 1). At month 12, participants were re-randomized to receive ACP 2 mg/eye via IVT injections monthly from month12 through month 23 (Year 2).
Sham comparator: Sham - Participants received sham injections; through Month 11 (Year 1). At month 12, participants continued to receive monthly sham administration from month 12 through month 23 (Year 2).
Experimental: Avacincaptad pegol and Sham - Participants who received ACP 2mg monthly through Month 11 (Year 1) were re-randomized at month 12, to receive ACP 2 mg/eye via IVT injections every other month at months 13, 15, 17, 19, 21, and 23 and sham injections at months 12, 14, 16,18, 20, and 22.
Treatment: Drugs: Avacincaptad Pegol
Avacincaptad Pegol Intravitreal Injection
Treatment: Drugs: Sham
Sham Administration (includes placement of the blunt opening of an empty, needleless syringe barrel on the conjunctiva in the inferotemporal quadrant of the eyeball to simulate the pressure of an injection)
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
The Mean Rate of Growth (Slope) Estimated Based on GA Area Measured by Autofluorescence (FAF) at 3 Time Points: Baseline, Month 6, and Month 12
Query!
Assessment method [1]
0
0
GA was associated with age-related macular degeneration (AMD) and caused bilateral, progressive, and irreversible loss of retinal tissue (photoreceptors, retinal pigment epithelium, and choriocapillaris) leading to a permanent loss of visual function and blindness. The least squares mean used to determine mean rate of change in GA growth (slope) was measured by FAF. LS mean \& SE were based on square-root transformation.
Query!
Timepoint [1]
0
0
Baseline to month 12
Query!
Primary outcome [2]
0
0
The Mean Rate of Growth (Slope) Estimated Based on GA Area Measured by FAF at 5 Timepoints: Baseline, Month 6, Month 12, Month 18, and Month 24
Query!
Assessment method [2]
0
0
GA was associated with AMD and caused bilateral, progressive, and irreversible loss of retinal tissue (photoreceptors, retinal pigment epithelium, and choriocapillaris) leading to a permanent loss of visual function and blindness. The least square mean rate of GA growth (slope) was measured by FAF. LS mean \& SE were based on untransformed data.
Query!
Timepoint [2]
0
0
Baseline to month 24
Query!
Secondary outcome [1]
0
0
Change From Baseline in Best Corrected Visual Acuity (BCVA) Using Early Treatment Diabetic Retinopathy Study (ETDRS) Letters at 24 Months
Query!
Assessment method [1]
0
0
BCVA was assessed using ETDRS visual acuity testing charts. The ETDRS Visual Acuity Score (VAS) is defined as the number of letters read on the ETDRS chart. Minimum and maximum possible scores are 0-100. A higher score represented better visual functioning. A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening.
Query!
Timepoint [1]
0
0
Baseline and month 24
Query!
Secondary outcome [2]
0
0
Change From Baseline in Low Luminance (LL) BCVA Using ETDRS Letters at 24 Months
Query!
Assessment method [2]
0
0
BCVA was assessed using ETDRS visual acuity testing charts. The ETDRS VAS is defined as the number of letters read on the ETDRS chart. Minimum and maximum possible scores are 0-100. A higher score represented better visual functioning. A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening. LL BCVA was measured by placing a 2.0 log unit neutral density filter over the best correction for that eye and having the participant read the normally illuminated ETDRS chart.
Query!
Timepoint [2]
0
0
Baseline and month 24
Query!
Secondary outcome [3]
0
0
Change From Baseline in Visual Function Questionnaire (VFQ-25) Composite Scores at 6, 12 and 18 Months
Query!
Assessment method [3]
0
0
The National Eye Institute Visual Function Questionnaire-25 (VFQ-25) measured the influence of visual disability and visual symptoms on general health domains. The VFQ-25 consisted of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. A higher score represented better visual functioning. Each item was then converted to a 0 to 100 scale so that the lowest and highest possible scores were set at 0 and 100 points, respectively. Each subscale score had a range of 0 to 100 inclusive and were calculated from the re-scaled raw data. A composite score was derived based on the average of the 11 vision-related subscales.
Query!
Timepoint [3]
0
0
Baseline, months 6, 12, and 18
Query!
Secondary outcome [4]
0
0
Change From Baseline in Visual Function Questionnaire (VFQ-25) Composite Scores at 24 Months
Query!
Assessment method [4]
0
0
The National Eye Institute Visual Function Questionnaire-25 (VFQ-25) measured the influence of visual disability and visual symptoms on general health domains. The VFQ-25 consisted of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. A higher score represented better visual functioning. Each item was then converted to a 0 to 100 scale so that the lowest and highest possible scores were set at 0 and 100 points, respectively. Each subscale score had a range of 0 to 100 inclusive and were calculated from the re-scaled raw data. A composite score was derived based on the average of the 11 vision-related subscales.
Query!
Timepoint [4]
0
0
Baseline and month 24
Query!
Secondary outcome [5]
0
0
Number of Participants With Categorical One-level Loss in VFQ-25 Subscale
Query!
Assessment method [5]
0
0
The National Eye Institute VFQ-25 measured the influence of visual disability and visual symptoms on general health domains. The VFQ-25 consisted of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. A higher score represented better visual functioning. Each item was then converted to a 0 to 100 scale so that the lowest and highest possible scores were set at 0 and 100 points, respectively.Categorical one-level loss in each item was defined as decline of one or more levels at Month 24 on the original scale from Baseline (equivalently 20 points for general vision and 25 points for other vision items in a 0 to 100 scale).
Query!
Timepoint [5]
0
0
Baseline up to month 24
Query!
Secondary outcome [6]
0
0
Time to Persistent Vision Loss
Query!
Assessment method [6]
0
0
Vision loss event was defined as a loss of = 15 letters (equivalent to a loss of 3 lines on the ETDRS chart) in BCVA from Baseline measured at any two or more consecutive visits up to Month 24. These parameters were chosen as a 3-line BCVA loss (equivalent to doubling of visual angle) is widely recognized as a significant deterioration in vision and a minimum of two consecutive visits was representative of persistent disease progression. BCVA was assessed using ETDRS visual acuity testing charts. The ETDRS VAS was defined as the number of letters read on the ETDRS chart. Min and max possible scores are 0-100. A higher score represents better visual functioning. Kaplan-Meier method was used for analysis. Participants with an event were reported and not the median time to event.
Query!
Timepoint [6]
0
0
Baseline up to month 24
Query!
Eligibility
Key inclusion criteria
* Subjects of either gender aged = 50 years
* Diagnosis of Non-foveal GA secondary to dry AMD
Query!
Minimum age
50
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Any prior treatment for AMD (dry or wet) or any prior intravitreal treatment for any indication in either eye, except oral supplements of vitamins and minerals
* Any intraocular surgery or thermal laser within 3 months of trial entry.
* Any prior thermal laser in the macular region, regardless of indication
* Any ocular or periocular infection (including blepharitis), or ocular surface inflammation in the past 12 weeks.
* Previous therapeutic radiation in the region of the study eye
* Any sign of diabetic retinopathy in either eye
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people assessing the outcomes
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
22/06/2020
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
22/08/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
448
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
0
0
Sydney Eye Hospital - Sydney
Query!
Recruitment hospital [2]
0
0
Sydney Retina Clinic and Day Surgery - Sydney
Query!
Recruitment hospital [3]
0
0
Royal Victorian Eye & Ear Hospital - East Melbourne
Query!
Recruitment postcode(s) [1]
0
0
2000 - Sydney
Query!
Recruitment postcode(s) [2]
0
0
3002 - East Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Colorado
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Connecticut
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Hawaii
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Illinois
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Indiana
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Iowa
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Kansas
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Louisiana
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Maryland
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Massachusetts
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Michigan
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Minnesota
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Missouri
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Nevada
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
New Jersey
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
New York
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
North Carolina
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Ohio
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Oregon
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Pennsylvania
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
South Carolina
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
South Dakota
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Tennessee
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Texas
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Utah
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Virginia
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Washington
Query!
Country [31]
0
0
Argentina
Query!
State/province [31]
0
0
Caba
Query!
Country [32]
0
0
Argentina
Query!
State/province [32]
0
0
Santa Fe
Query!
Country [33]
0
0
Argentina
Query!
State/province [33]
0
0
Buenos Aires
Query!
Country [34]
0
0
Argentina
Query!
State/province [34]
0
0
Córdoba
Query!
Country [35]
0
0
Argentina
Query!
State/province [35]
0
0
Mendoza
Query!
Country [36]
0
0
Argentina
Query!
State/province [36]
0
0
Rosario
Query!
Country [37]
0
0
Austria
Query!
State/province [37]
0
0
Graz
Query!
Country [38]
0
0
Austria
Query!
State/province [38]
0
0
Innsbruck
Query!
Country [39]
0
0
Austria
Query!
State/province [39]
0
0
Vienna
Query!
Country [40]
0
0
Belgium
Query!
State/province [40]
0
0
Brussels
Query!
Country [41]
0
0
Brazil
Query!
State/province [41]
0
0
Belo Horizonte
Query!
Country [42]
0
0
Brazil
Query!
State/province [42]
0
0
São Paulo
Query!
Country [43]
0
0
Brazil
Query!
State/province [43]
0
0
Vila Clementino
Query!
Country [44]
0
0
Canada
Query!
State/province [44]
0
0
Alberta
Query!
Country [45]
0
0
Canada
Query!
State/province [45]
0
0
British Columbia
Query!
Country [46]
0
0
Canada
Query!
State/province [46]
0
0
Ontario
Query!
Country [47]
0
0
Canada
Query!
State/province [47]
0
0
Ottawa
Query!
Country [48]
0
0
Colombia
Query!
State/province [48]
0
0
Antioquia
Query!
Country [49]
0
0
Colombia
Query!
State/province [49]
0
0
Bogotá
Query!
Country [50]
0
0
Croatia
Query!
State/province [50]
0
0
Osijek
Query!
Country [51]
0
0
Czechia
Query!
State/province [51]
0
0
Smichov
Query!
Country [52]
0
0
Estonia
Query!
State/province [52]
0
0
Tallin
Query!
Country [53]
0
0
Estonia
Query!
State/province [53]
0
0
Tartu
Query!
Country [54]
0
0
France
Query!
State/province [54]
0
0
Bordeaux
Query!
Country [55]
0
0
France
Query!
State/province [55]
0
0
Créteil
Query!
Country [56]
0
0
France
Query!
State/province [56]
0
0
Dijon
Query!
Country [57]
0
0
France
Query!
State/province [57]
0
0
Lyon
Query!
Country [58]
0
0
France
Query!
State/province [58]
0
0
Marseille
Query!
Country [59]
0
0
France
Query!
State/province [59]
0
0
Nantes
Query!
Country [60]
0
0
France
Query!
State/province [60]
0
0
Paris
Query!
Country [61]
0
0
France
Query!
State/province [61]
0
0
Saint-Cyr-sur-Loire
Query!
Country [62]
0
0
France
Query!
State/province [62]
0
0
Écully
Query!
Country [63]
0
0
Germany
Query!
State/province [63]
0
0
Aachen
Query!
Country [64]
0
0
Germany
Query!
State/province [64]
0
0
Bonn
Query!
Country [65]
0
0
Germany
Query!
State/province [65]
0
0
Göttingen
Query!
Country [66]
0
0
Germany
Query!
State/province [66]
0
0
Hamburg
Query!
Country [67]
0
0
Germany
Query!
State/province [67]
0
0
Hanover
Query!
Country [68]
0
0
Germany
Query!
State/province [68]
0
0
Köln
Query!
Country [69]
0
0
Germany
Query!
State/province [69]
0
0
Leipzig
Query!
Country [70]
0
0
Germany
Query!
State/province [70]
0
0
Lübeck
Query!
Country [71]
0
0
Germany
Query!
State/province [71]
0
0
Mainz
Query!
Country [72]
0
0
Germany
Query!
State/province [72]
0
0
Munich
Query!
Country [73]
0
0
Germany
Query!
State/province [73]
0
0
Münster
Query!
Country [74]
0
0
Germany
Query!
State/province [74]
0
0
Tübingen
Query!
Country [75]
0
0
Hungary
Query!
State/province [75]
0
0
Budapest
Query!
Country [76]
0
0
Hungary
Query!
State/province [76]
0
0
Debrecen
Query!
Country [77]
0
0
Hungary
Query!
State/province [77]
0
0
Nyiregyhaza
Query!
Country [78]
0
0
Hungary
Query!
State/province [78]
0
0
Pécs
Query!
Country [79]
0
0
Hungary
Query!
State/province [79]
0
0
Szeged
Query!
Country [80]
0
0
Israel
Query!
State/province [80]
0
0
Ashkelon
Query!
Country [81]
0
0
Israel
Query!
State/province [81]
0
0
Be'er Ya'aqov
Query!
Country [82]
0
0
Israel
Query!
State/province [82]
0
0
Haifa
Query!
Country [83]
0
0
Israel
Query!
State/province [83]
0
0
Holon
Query!
Country [84]
0
0
Israel
Query!
State/province [84]
0
0
Jerusalem
Query!
Country [85]
0
0
Israel
Query!
State/province [85]
0
0
Petah tikva
Query!
Country [86]
0
0
Israel
Query!
State/province [86]
0
0
Re?ovot
Query!
Country [87]
0
0
Israel
Query!
State/province [87]
0
0
Tel Aviv
Query!
Country [88]
0
0
Italy
Query!
State/province [88]
0
0
Ancona
Query!
Country [89]
0
0
Italy
Query!
State/province [89]
0
0
Bologna
Query!
Country [90]
0
0
Italy
Query!
State/province [90]
0
0
Chieti
Query!
Country [91]
0
0
Italy
Query!
State/province [91]
0
0
Ferrara
Query!
Country [92]
0
0
Italy
Query!
State/province [92]
0
0
Florence
Query!
Country [93]
0
0
Italy
Query!
State/province [93]
0
0
Milan
Query!
Country [94]
0
0
Italy
Query!
State/province [94]
0
0
Naples
Query!
Country [95]
0
0
Italy
Query!
State/province [95]
0
0
Padova
Query!
Country [96]
0
0
Italy
Query!
State/province [96]
0
0
Pisa
Query!
Country [97]
0
0
Italy
Query!
State/province [97]
0
0
Roma
Query!
Country [98]
0
0
Italy
Query!
State/province [98]
0
0
Udine
Query!
Country [99]
0
0
Latvia
Query!
State/province [99]
0
0
Riga
Query!
Country [100]
0
0
Poland
Query!
State/province [100]
0
0
Bydgoszcz
Query!
Country [101]
0
0
Poland
Query!
State/province [101]
0
0
Tarnowskie Góry
Query!
Country [102]
0
0
Poland
Query!
State/province [102]
0
0
Wroclaw
Query!
Country [103]
0
0
Poland
Query!
State/province [103]
0
0
Lódz
Query!
Country [104]
0
0
Spain
Query!
State/province [104]
0
0
Barcelona
Query!
Country [105]
0
0
Spain
Query!
State/province [105]
0
0
Bilbao
Query!
Country [106]
0
0
Spain
Query!
State/province [106]
0
0
Córdoba
Query!
Country [107]
0
0
Spain
Query!
State/province [107]
0
0
Majadahonda
Query!
Country [108]
0
0
Spain
Query!
State/province [108]
0
0
Pamplona
Query!
Country [109]
0
0
Spain
Query!
State/province [109]
0
0
Santiago De Compostela
Query!
Country [110]
0
0
Spain
Query!
State/province [110]
0
0
Valencia
Query!
Country [111]
0
0
Spain
Query!
State/province [111]
0
0
Valladolid
Query!
Country [112]
0
0
Spain
Query!
State/province [112]
0
0
Zaragoza
Query!
Country [113]
0
0
United Kingdom
Query!
State/province [113]
0
0
Hull
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
IVERIC bio, Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The objectives of this study was to evaluate the safety and efficacy of avacincaptad pegol intravitreal administration in participants with geographic atrophy secondary to age-related macular degeneration (AMD)
Query!
Trial website
https://clinicaltrials.gov/study/NCT04435366
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Clinical study report (CSR)
Query!
When will data be available (start and end dates)?
Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
Query!
Available to whom?
Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: https://www.clinicaltrials.astellas.com/transparency/
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/66/NCT04435366/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/66/NCT04435366/SAP_002.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT04435366
Download to PDF